Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial

Table 11

Severity of symptoms during the medical observation period.

Follow-up timepoint	Classification of symptoms	N = 24		value
		LH group; (N = 7)	Control group; (N = 17)
Isolation period	Level 1, N (%)	6 (85.71)	9 (52.94)	0.1402
	Level 2, N (%)	1 (14.29)	7 (41.18)
	Level 3, N (%)	0 (0.00)	1 (5.88)